Lenalidomide: Myelodysplastic syndromes with del(5q) and beyond.
Sign Up to like & getrecommendations! Published in 2017 at "Seminars in hematology"
DOI: 10.1053/j.seminhematol.2017.06.003
Abstract: Myelodysplastic syndrome (MDS) with deletion 5q (del(5q)) is a distinct clinical and pathological disease subset that is exquisitely sensitive to lenalidomide for the treatment of red blood cell transfusion-dependent anemia. Although lenalidomide has erythropoeitic promoting… read more here.
Keywords: non del; del; del mds; myelodysplastic syndromes ... See more keywords
Genomic Biomarkers Predict Response/Resistance to Lenalidomide in Non-Del(5q) Myelodysplastic Syndromes
Sign Up to like & getrecommendations! Published in 2018 at "Blood"
DOI: 10.1182/blood-2018-99-114681
Abstract: Lenalidomide (Len) is FDA approved for the treatment of patients (pts) with lower-risk, transfusion-dependent myelodysplastic syndromes (MDS) with deletion(5q). It is frequently used in lower-risk pts with non-del(5q) MDS, with a transfusion independence response rate… read more here.
Keywords: non del; board directors; membership entity; directors advisory ... See more keywords